Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 14/20 | 0.74 |
| ▸ | EHMT1 | Q9H9B1 | 13/20 | 0.74 |
| ▸ | EGFR | P00533 | 2/20 | 0.59 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.59 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.58 |
| ▸ | SPIN1 | Q9Y657 | 1/20 | 0.57 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | BCR | P11274 | 1/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29636829 | 0.99 | EHMT2 (0.76) | EHMT2EHMT1EGFRDNMT1FGFR2 | |
| SCHEMBL8526894 | 0.99 | EHMT2 (0.76) | EHMT2EHMT1EGFRDNMT1FGFR2 | |
| Hydrochloric Acid SCHEMBL6433786 | 0.98 | EHMT2 (0.74) | EHMT2EHMT1EGFRDNMT1FGFR2 | |
| SCHEMBL2746706 | 0.93 | EHMT2 (0.67) | EHMT2EHMT1EGFRDNMT1EPHA2 | |
| SCHEMBL2152700 | 0.91 | EHMT2 (0.64) | EHMT2EHMT1EGFREPHA2KDR | |
| SCHEMBL903068 | 0.89 | EGFR (0.64) | EHMT2EHMT1EGFRKDREPHB4 | |
| SCHEMBL2152791 | 0.89 | EHMT2 (0.62) | EHMT2EHMT1EGFRSRC | |
| SCHEMBL5097860 | 0.89 | EGFR (0.64) | EHMT2EHMT1EGFRKDREPHB4 | |
| Hydrochloric Acid SCHEMBL6432089 | 0.88 | EGFR (0.62) | EHMT2EHMT1EGFRKDREPHB4 | |
| SCHEMBL16707263 | 0.87 | EHMT2 (0.56) | EHMT2EHMT1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109988110-B | 4-phenoxy quinoline sulfonylurea compound, intermediate for synthesizing the compound and its preparation method and use | 威海海洋生物医药产业技术研究院有限公司 | 2022-07-01 | — | — | CN | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20060241115-A1 | Compounds and methods of use | AMGEN INC. | 2006-10-26 | — | — | US | disclosed |
| EP-1713484-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241115-A1 | Compounds and methods of use | HGF, HGFAC, MET | EHMT2 2119/4885EHMT1 1923/4885EGFR 129/4885 |
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | EHMT2 2119/4885EHMT1 1923/4885EGFR 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.